Foeglein Agnes, Walter Hauke
National Reference Center for Human Retroviruses, Institute for Clinical and Molecular Virology at the University of Erlangen-Nuremberg, Germany.
Eur J Med Res. 2007 Oct 15;12(9):473-82.
Several studies showed that the upcoming drug class of CCR5 coreceptor antagonists have potent virological and immunological activity in treatment experienced patients. In patients failing a CCR5 antagonists-based regimen, the emergence of CXCR4-tropic viral variants has been demonstrated. Clonal analysis of viral isolates from a limited number of patients revealed that these CXCR4-tropic strains did not develop by mutation of a CCR5-tropic virus during therapy, but emerged from a minor population of CXCR4-tropic variants already present in the patients at baseline. Obviously, screening for CXCR4-tropic strains with a functional assay and subsequent exclusion of positive individuals from clinical studies could not completely avoid the selection of CXCR4-tropic strains during failure. But emergence of CXCR4-tropic viruses on therapy may require a critical threshold of CXCR4 viral load at baseline, which may not be the case in patients with a very low proportion of CXCR4-using variants. Therefore, this review addresses to what extent currently available methods are suitable to detect CXCR4-tropic strains in clinical settings. Available functional assays are based on recombinant viruses. These assays are generally restricted to a few laboratories and cannot be easily included in daily clinical settings. Whereas minority detection limits of sequence analyses are generally high with 15 to 30%, functional assays achieve lower detection limits for minorities of 5%. Sequence analyses require an additional interpretation step, and the accuracy of interpretation from clinical samples by current predictions systems has to be improved. In consequence, new methods are arising: genotyping may be improved by hybridisation assays, which quantify CXCR4-tropic viruses by their homology down to 1% minorities, and functional non-infectious cell fusion assays may overcome security restrictions and make phenotypic methods suitable for routine clinical laboratory practise. The highly sensitive detection of CXCR4-tropic viruses may provide the opportunity to clarify the conditions of clinical relevance for CXCR4-tropic minorities.
多项研究表明,即将出现的CCR5共受体拮抗剂药物类别在经治患者中具有强大的病毒学和免疫学活性。在基于CCR5拮抗剂的治疗方案失败的患者中,已证实出现了嗜CXCR4病毒变体。对少数患者的病毒分离株进行克隆分析发现,这些嗜CXCR4毒株并非在治疗期间由嗜CCR5病毒突变产生,而是源自患者基线时就已存在的少量嗜CXCR4变体。显然,通过功能检测筛选嗜CXCR4毒株并随后将阳性个体排除在临床研究之外,并不能完全避免在治疗失败期间选择嗜CXCR4毒株。但是治疗期间嗜CXCR4病毒的出现可能需要基线时CXCR4病毒载量达到临界阈值,而对于使用CXCR4变体比例非常低的患者可能并非如此。因此,本综述探讨了目前可用的方法在多大程度上适用于在临床环境中检测嗜CXCR4毒株。现有的功能检测基于重组病毒。这些检测通常仅限于少数实验室,不易纳入日常临床环境。虽然序列分析的少数群体检测限通常较高,为15%至30%,但功能检测对少数群体的检测限可低至5%。序列分析需要额外的解读步骤,并且当前预测系统对临床样本解读的准确性有待提高。因此,新方法不断涌现:基因分型可通过杂交检测得到改进,杂交检测可通过同源性对嗜CXCR4病毒进行定量,低至1%的少数群体,而功能性非感染性细胞融合检测可能会克服安全性限制,使表型方法适用于常规临床实验室实践。对嗜CXCR4病毒的高度敏感检测可能为阐明嗜CXCR4少数群体的临床相关条件提供机会。